MCID: SLV026
MIFTS: 58

Salivary Gland Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Salivary Gland Carcinoma

MalaCards integrated aliases for Salivary Gland Carcinoma:

Name: Salivary Gland Carcinoma 12 15
Salivary Gland Cancer 12 37 55 43 15
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12
Malignant Neoplasm of Salivary Gland 12
Major Salivary Gland Carcinoma 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0050904 DOID:8850
KEGG 37 H01508
ICD9CM 35 142.8
ICD10 33 C08
UMLS 72 C0153362

Summaries for Salivary Gland Carcinoma

KEGG : 37
Salivary gland carcinomas are rare tumours representing about 0.5% of all malignancies and less than 5 % of all head and neck cancers. These are a heterogeneous group of tumors that include 24 histologically distinct tumor types. Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor in adults and children. The most common genetic alteration in MECs is a unique translocation t(11;19)(q21;p13) producing the MECT1-MAML2 fusion protein. This fusion transcript can activate transcription of targets in the Notch pathway. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) overexpression is present in a minority of MECs and is associated with higher rate of metastasis and worse overall survival. Recent studies have evaluated the epidermal growth factor receptor family including EGFR and HER2 as potential therapeutic targets.

MalaCards based summary : Salivary Gland Carcinoma, also known as salivary gland cancer, is related to mucoepidermoid carcinoma and adenoid cystic carcinoma. An important gene associated with Salivary Gland Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Notch signaling pathway and MAPK signaling pathway. The drugs Iodine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, testes and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

MedlinePlus : 43 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

Related Diseases for Salivary Gland Carcinoma

Diseases in the Salivary Gland Carcinoma family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 31.9 MAML2 EGFR CRTC3 CRTC1
2 adenoid cystic carcinoma 31.0 SERPINA3 NFIB KIT CYLD
3 renal cell carcinoma, nonpapillary 30.3 MET KIT HGF EGFR
4 salivary gland disease 28.1 NFIB MAML2 ISL1 CYLD CRTC3 CRTC1
5 salivary gland cancer, adult 12.7
6 salivary gland cancer, childhood 12.4
7 parotid gland cancer 11.6
8 cylindromatosis, familial 11.4
9 multiple familial trichoepithelioma 11.4
10 sublingual gland cancer 11.3
11 malignant peritoneal mesothelioma 10.7 EGFR CDKN2A
12 deafness, autosomal recessive 39 10.7 MET HGF
13 infiltrating angiolipoma 10.6 MDM2 CDKN2A
14 anaplastic oligodendroglioma 10.6 EGFR CDKN2A
15 acral lentiginous melanoma 10.6 MET KIT CDKN2A
16 small cell carcinoma 10.6 KIT EGFR CDKN2A
17 chordoma 10.6 MET EGFR CDKN2A
18 doxorubicin induced cardiomyopathy 10.6 MET HGF EGFR
19 deafness, autosomal recessive 97 10.6 MET HGF
20 endometrial squamous cell carcinoma 10.6 MET HGF CDKN2A
21 familial renal papillary carcinoma 10.6 MET HGF EGFR
22 grade iii astrocytoma 10.6 MDM2 EGFR CDKN2A
23 central nervous system melanocytic neoplasm 10.6 KIT HGF CDKN2A
24 spinal chordoma 10.6 MET HGF EGFR
25 nervous system cancer 10.6 MDM2 EGFR CDKN2A
26 cellular schwannoma 10.6 SOX2 MDM2 CDKN2A
27 central nervous system cancer 10.6 SOX2 EGFR CDKN2A
28 adenoid basal cell carcinoma 10.6 KIT CDKN2A
29 ocular cancer 10.5 SOX2 MDM2 CDKN2A
30 respiratory system cancer 10.5 MET EGFR CDKN2A
31 li-fraumeni syndrome 10.5 MDM2 EGFR CDKN2A
32 sarcoma, synovial 10.5 MET MDM2 KIT
33 adenocarcinoma 10.5
34 acinar cell carcinoma 10.5
35 pleomorphic adenoma 10.5
36 spindle cell synovial sarcoma 10.5 MET ISL1 HGF
37 conventional fibrosarcoma 10.5 MDM2 KIT
38 large cell medulloblastoma 10.5 MET HGF
39 undifferentiated embryonal sarcoma of the liver 10.5 SERPINA3 MDM2
40 malignant peripheral nerve sheath tumor 10.5 MDM2 KIT EGFR CDKN2A
41 lacrimal system cancer 10.5 NFIB MAML2
42 gastrointestinal system cancer 10.5 MET KIT EGFR CDKN2A
43 cerebrum cancer 10.4 SOX2 MDM2 EGFR CDKN2A
44 supratentorial cancer 10.4 SOX2 MDM2 EGFR CDKN2A
45 adenoma 10.4
46 lacrimal gland mucoepidermoid carcinoma 10.4 MAML2 CRTC1
47 embryonal sarcoma 10.4 SERPINA3 MDM2 KIT
48 polymorphous low-grade adenocarcinoma 10.4
49 connective tissue cancer 10.4 SERPINA3 MDM2 KIT
50 adamantinoma of long bones 10.4 SOX2 MDM2 EGFR CDKN2A

Graphical network of the top 20 diseases related to Salivary Gland Carcinoma:



Diseases related to Salivary Gland Carcinoma

Symptoms & Phenotypes for Salivary Gland Carcinoma

GenomeRNAi Phenotypes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.91 EGFR
2 Decreased viability GR00221-A-1 9.91 CDKN2A EGFR HGF SOX2 CYLD KIT
3 Decreased viability GR00221-A-2 9.91 HGF CYLD
4 Decreased viability GR00221-A-3 9.91 CDKN2A
5 Decreased viability GR00221-A-4 9.91 BRD3 CDKN2A EGFR HGF SOX2
6 Decreased viability GR00301-A 9.91 CYLD KIT
7 Decreased viability GR00402-S-2 9.91 BRD3 CDKN2A EGFR HGF SOX2 CYLD

MGI Mouse Phenotypes related to Salivary Gland Carcinoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 CDKN2A CRTC1 CRTC3 CYLD EGFR HGF
2 endocrine/exocrine gland MP:0005379 10.31 CDKN2A CRTC1 CYLD EGFR ISL1 KIT
3 cardiovascular system MP:0005385 10.23 CDKN2A EGFR HGF ISL1 KIT MDM2
4 mortality/aging MP:0010768 10.23 CDKN2A CRTC3 CYLD EGFR HGF ISL1
5 digestive/alimentary MP:0005381 10.21 CDKN2A CYLD EGFR ISL1 KIT MDM2
6 embryo MP:0005380 10.15 CDKN2A EGFR HGF ISL1 KIT MDM2
7 craniofacial MP:0005382 10.11 EGFR ISL1 KIT MDM2 MET NFIB
8 integument MP:0010771 10.11 CDKN2A CYLD EGFR ISL1 KIT MDM2
9 liver/biliary system MP:0005370 10.08 CDKN2A CRTC3 EGFR HGF KIT MDM2
10 neoplasm MP:0002006 10.06 CDKN2A CYLD EGFR ISL1 KIT MDM2
11 limbs/digits/tail MP:0005371 10.04 CRTC3 CYLD EGFR ISL1 KIT MDM2
12 muscle MP:0005369 10.03 CDKN2A CRTC3 EGFR ISL1 KIT MDM2
13 no phenotypic analysis MP:0003012 9.97 CDKN2A EGFR HGF ISL1 KIT MDM2
14 normal MP:0002873 9.92 CYLD EGFR ISL1 KIT MDM2 MET
15 reproductive system MP:0005389 9.81 CDKN2A CRTC1 EGFR ISL1 KIT MDM2
16 pigmentation MP:0001186 9.65 CDKN2A EGFR KIT MDM2 SOX2
17 respiratory system MP:0005388 9.5 CDKN2A CYLD EGFR KIT MET NFIB
18 vision/eye MP:0005391 9.23 CDKN2A EGFR ELMO3 ISL1 KIT MET

Drugs & Therapeutics for Salivary Gland Carcinoma

Drugs for Salivary Gland Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
3
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
4
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
5
leucovorin Approved Phase 3 58-05-9 143 6006
6
Promethazine Approved, Investigational Phase 3 60-87-7 4927
7
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
14 cadexomer iodine Phase 3
15 Antimetabolites Phase 3
16 Antimetabolites, Antineoplastic Phase 3
17 Neurotransmitter Agents Phase 3
18 Cholinergic Agents Phase 3
19 Peripheral Nervous System Agents Phase 3
20 Muscarinic Agonists Phase 3
21 Autonomic Agents Phase 3
22 Cola Phase 3
23 Liver Extracts Phase 3
24 Folic Acid Antagonists Phase 3
25 Folate Phase 3
26 Vitamin B9 Phase 3
27 Vitamin B Complex Phase 3
28 Dermatologic Agents Phase 3
29 Nucleic Acid Synthesis Inhibitors Phase 3
30 Analgesics Phase 3
31 Antidepressive Agents Phase 3
32 Hypnotics and Sedatives Phase 3
33 Histamine Antagonists Phase 3
34 Central Nervous System Depressants Phase 3
35
Histamine Phosphate Phase 3 51-74-1 65513
36 Psychotropic Drugs Phase 3
37 Antidepressive Agents, Tricyclic Phase 3
38 Anesthetics, Intravenous Phase 3
39 Narcotics Phase 3
40 Analgesics, Opioid Phase 3
41 Adjuvants, Anesthesia Phase 3
42 Anesthetics, General Phase 3
43 Anesthetics Phase 3
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
45
Nintedanib Approved Phase 2 656247-17-5 56843413
46
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
47
Temoporfin Approved, Investigational Phase 2 122341-38-2
48
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
49
Indinavir Approved Phase 2 150378-17-9 5362440
50
Gemcitabine Approved Phase 2 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 127)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
2 A Multicenter Randomized Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Parotid Tumors Unknown status NCT01216800 Phase 3
3 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
4 Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00003592 Phase 3 methotrexate;paclitaxel
5 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
6 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
7 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
9 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
10 Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study Unknown status NCT01703455 Phase 2 Sorafenib
11 Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study Unknown status NCT02558387 Phase 2 BIBF1120
12 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
13 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
14 A Multicenter, Multi-National, Open-Label, Single Group, Single and Multiple Dose Study of Foscan-Mediated Photodynamic Therapy (PDT) for the Palliative Treatment of Recurrent, Refractory or Second Primary Squamous Cell Carcinomas of the Head and Neck in Patients Considered to be Incurable With Surgery or Radiotherapy Unknown status NCT00003856 Phase 2 temoporfin
15 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
16 Gemcitabine for Advanced Salivary Cancer: A Phase II Study Completed NCT00003744 Phase 2 gemcitabine
17 PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES Completed NCT00002632 Phase 2 paclitaxel
18 Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers Completed NCT01613768 Phase 2 eribulin mesylate
19 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
20 A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas Completed NCT00045669 Phase 2 imatinib mesylate
21 A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
22 Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
23 Phase 2 Study Assessing the Impact of Parenteral Administration of the Immunomodulater Oral IMPACT® for Postoperative Radiochemotherapy in Patients With Carcinoma of the Head and Neck Completed NCT00559156 Phase 2 cisplatin
24 Pilot Study of the Relationship Between EF5 Uptake and Concentration of Oxygen-Related Metabolites in Head and Neck Cancer Completed NCT00049140 Phase 2 EF5
25 Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198) Completed NCT00509002 Phase 2 Gefitinib
26 Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck Completed NCT00738868 Phase 2
27 Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck Carcinoma Completed NCT00040807 Phase 2 docetaxel;irinotecan hydrochloride
28 Phase I/II Trial of the Epothilone B Analogue BMS 247550 (NSC 710428)/Cisplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed NCT00057850 Phase 1, Phase 2 cisplatin;ixabepilone
29 Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck Completed NCT00003264 Phase 2 cisplatin;gemcitabine hydrochloride
30 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
31 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
32 Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
33 Pilot Randomized Trial Of Adjuvant Celecoxib In Patients With Early Stage Head And Neck And Non-Small Cell Lung Cancers Completed NCT00058006 Phase 2 celecoxib
34 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
35 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
36 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
37 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
38 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
39 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
40 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
41 Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers Recruiting NCT03749460 Phase 1, Phase 2
42 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) Recruiting NCT02628067 Phase 2
43 Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland Recruiting NCT03146650 Phase 2
44 The Efficacy of Cabozantinib in Advanced SAlivary Gland Cancer Patients, a Phase II Clinical Trial Recruiting NCT03729297 Phase 2 Cabozantinib
45 A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers Recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab
46 Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111 Recruiting NCT03942653 Phase 2 Goserelin Acetate;Pembrolizumab
47 A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors Recruiting NCT01220583 Phase 2 cisplatin
48 A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs) Recruiting NCT01969578 Phase 2 bicalutamide + triptorelin;Cisplatin + Doxorubicin;Carboplatin + Paclitaxel
49 Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study. Recruiting NCT03360890 Phase 2 Pembrolizumab;Docetaxel
50 A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects With NTRK Fusion-positive Tumors Recruiting NCT02576431 Phase 2 BAY2757556 (Larotrectinib, Vitrakvi)

Search NIH Clinical Center for Salivary Gland Carcinoma

Genetic Tests for Salivary Gland Carcinoma

Anatomical Context for Salivary Gland Carcinoma

MalaCards organs/tissues related to Salivary Gland Carcinoma:

41
Salivary Gland, Testes, Breast, Lymph Node, Lung, Thyroid, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Carcinoma:

19
Salivary Gland

Publications for Salivary Gland Carcinoma

Articles related to Salivary Gland Carcinoma:

(show top 50) (show all 615)
# Title Authors PMID Year
1
Auriculotemporal Nerve Involvement in Parotid Bed Malignancy. 17
30894024 2019
2
Is HIF1-a deregulated in malignant salivary neoplasms? 17
30902790 2019
3
Expression of MIF, Beclin1, and LC3 in human salivary gland adenoid cystic carcinoma and its prognostic value. 17
31096436 2019
4
CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. 9 38
19159612 2009
5
Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. 9 38
18355439 2008
6
Expression and cellular localization of TSC-22 in normal salivary glands and salivary gland tumors: implications for tumor cell differentiation. 9 38
18288391 2008
7
Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. 9 38
16469527 2006
8
CD151 forms a functional complex with c-Met in human salivary gland cancer cells. 9 38
16139245 2005
9
TSC-22 (TGF-beta stimulated clone-22): a novel molecular target for differentiation-inducing therapy in salivary gland cancer. 9 38
15379637 2004
10
Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. 9 38
13679209 2003
11
Cytoplasmic TSC-22 (transforming growth factor-beta-stimulated clone-22) markedly enhances the radiation sensitivity of salivary gland cancer cells. 9 38
11944908 2002
12
Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines. 9 38
11836575 2002
13
Leucine zipper structure of TSC-22 (TGF-beta stimulated clone-22) markedly inhibits the anchorage-independent growth of salivary gland cancer cells. 9 38
11836610 2002
14
In vivo enhancement of chemosensitivity of human salivary gland cancer cells by overexpression of TGF-beta stimulated clone-22. 9 38
10854535 2000
15
Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line. 9 38
10879745 2000
16
Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. 9 38
9458104 1998
17
Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. 9 38
9459148 1998
18
The role of elective neck dissection in patients with adenoid cystic carcinoma of the head and neck. 38
30667061 2019
19
Prognostic markers in salivary gland cancer and their impact on survival. 38
31246357 2019
20
Multicenter study of carbon-ion radiation therapy for nonsquamous cell carcinomas of the oral cavity. 38
31369213 2019
21
HPV-Related Multiphenotypic Sinonasal Carcinoma: A Unique Case. 38
31405309 2019
22
Up-front F18-FDG PET/CT in suspected salivary gland carcinoma. 38
31102059 2019
23
Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. 38
31423558 2019
24
Examined and positive lymph nodes counts and lymph nodes ratio are associated with survival in major salivary gland cancer. 38
30905082 2019
25
Correlation of apparent diffusion coefficient with histopathological parameters of salivary gland cancer. 38
30975578 2019
26
Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on Tumoral heterogeneity and temporal concordance. 38
31430492 2019
27
Nivolumab in patients with rare head and neck carcinomas: A single center's experience. 38
31300270 2019
28
Radiation-Related Risk of Cancers of the Upper Digestive Tract among Japanese Atomic Bomb Survivors. 38
31356146 2019
29
Anatomic extent of lymph node metastases as an independent prognosticator in node-positive major salivary gland carcinoma: A study of the US SEER database and a Chinese multicenter cohort. 38
31253544 2019
30
High metastatic node number, not extranodal extension, as a node-related prognosticator in surgically treated patients with nodal metastatic salivary gland carcinoma. 38
30652371 2019
31
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients. 38
31232197 2019
32
Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection. 38
30721113 2019
33
The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: Results from the surveillance, epidemiology, and End Results dataset. 38
30472214 2019
34
Pretreatment assessment of hematologic and inflammatory markers in adenoid cystic carcinoma: neutrophil/lymphocyte ratio is associated with multiple recurrences. 38
30745209 2019
35
A retrospective multicenter study of sublingual gland carcinoma in Japan. 38
31104870 2019
36
Prognostic Value of Tumor Heterogeneity and SUVmax of Pretreatment 18F-FDG PET/CT for Salivary Gland Carcinoma With High-Risk Histology. 38
30932974 2019
37
New approaches in salivary gland carcinoma. 38
30844885 2019
38
Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study. 38
31028207 2019
39
Diplopia: a unique presentation of recurrence of a salivary gland carcinoma. 38
31061174 2019
40
Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review. 38
30649610 2019
41
Salivary gland carcinoma in Shanghai (2003-2012): an epidemiological study of incidence, site and pathology. 38
30975127 2019
42
ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma. 38
30374620 2019
43
Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin - high locoregional control rates after photon (chemo) radiotherapy - experience from a monocentric analysis. 38
31014362 2019
44
The HTN3-MSANTD3 Fusion Gene Defines a Subset of Acinic Cell Carcinoma of the Salivary Gland. 38
30520817 2019
45
Complications of radio- and radiochemotherapy in patients undergoing major salivary gland cancer surgery. 38
31249150 2019
46
Survival and characteristics of pediatric salivary gland cancer: A systematic review and meta-analysis. 38
30378272 2019
47
PTEN downregulates WD repeat‑containing protein 66 in salivary adenoid cystic carcinoma. 38
30569117 2019
48
Effective chemotherapy for submandibular gland carcinoma ex pleomorphic adenoma with lung metastasis after radiotherapy: A case report. 38
30968046 2019
49
Assessment of salivary endothelin-1 in patients with leukoplakia, submucous fibrosis, oral cancer and healthy individuals - a comparative study. 38
30858129 2019
50
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. 38
30771738 2019

Variations for Salivary Gland Carcinoma

Cosmic variations for Salivary Gland Carcinoma:

9 (show top 50) (show all 486)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6915468 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 48
2 COSM6845145 ZFHX3 salivary gland,major,carcinoma,NS c.8617G>A p.E2873K 16:72794065-72794065 36
3 COSM1659071 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5T 1:27428876-27428876 36
4 COSM6979379 TSHR salivary gland,major,carcinoma,NS c.1376C>T p.A459V 14:81143434-81143434 36
5 COSM6983845 TSC2 salivary gland,major,carcinoma,NS c.2276G>A p.R759K 16:2072904-2072904 36
6 COSM6939530 TSC2 salivary gland,major,carcinoma,NS c.2402C>T p.A801V 16:2074246-2074246 36
7 COSM6939527 TSC1 salivary gland,major,carcinoma,NS c.2684T>A p.V895D 9:132897552-132897552 36
8 COSM1659031 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 36
9 COSM1658989 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3854C>G p.T1285S 15:43422086-43422086 36
10 COSM43878 TP53 salivary gland,major,carcinoma,NS c.427G>A p.V143M 17:7675185-7675185 36
11 COSM10777 TP53 salivary gland,major,carcinoma,NS c.715A>G p.N239D 17:7674248-7674248 36
12 COSM10662 TP53 salivary gland,major,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 36
13 COSM10648 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 36
14 COSM10905 TP53 salivary gland,major,carcinoma,NS c.451C>T p.P151S 17:7675161-7675161 36
15 COSM43951 TP53 salivary gland,major,carcinoma,NS c.643A>G p.S215G 17:7674888-7674888 36
16 COSM69404 TP53 salivary gland,minor,carcinoma,NS c.994-1G>A p.? 17:7670716-7670716 36
17 COSM10659 TP53 salivary gland,major,carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 36
18 COSM46283 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 36
19 COSM10705 TP53 salivary gland,major,carcinoma,NS c.586C>T p.R196* 17:7674945-7674945 36
20 COSM43931 TP53 salivary gland,major,carcinoma,NS c.523C>A p.R175S 17:7675089-7675089 36
21 COSM11354 TP53 salivary gland,major,carcinoma,NS c.991C>T p.Q331* 17:7673537-7673537 36
22 COSM43680 TP53 salivary gland,major,carcinoma,NS c.523C>T p.R175C 17:7675089-7675089 36
23 COSM44119 TP53 salivary gland,major,carcinoma,NS c.483C>T p.A161A 17:7675129-7675129 36
24 COSM43797 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.550G>C p.D184H 17:7675062-7675062 36
25 COSM11552 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 36
26 COSM46282 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 36
27 COSM10758 TP53 salivary gland,major,carcinoma,NS c.659A>G p.Y220C 17:7674872-7674872 36
28 COSM44853 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 36
29 COSM10786 TP53 salivary gland,major,carcinoma,NS c.949C>T p.Q317* 17:7673579-7673579 36
30 COSM44850 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 36
31 COSM307275 TP53 salivary gland,major,carcinoma,NS c.96+1G>T p.? 17:7676381-7676381 36
32 COSM1659046 THRA salivary gland,mouth floor,carcinoma,NS c.1162C>T p.R388W 17:40093071-40093071 36
33 COSM6935085 TENT5C salivary gland,minor,carcinoma,NS c.833T>A p.F278Y 1:117623701-117623701 36
34 COSM6930930 TENT5C salivary gland,major,carcinoma,NS c.702G>C p.K234N 1:117623570-117623570 36
35 COSM6983859 TCF3 salivary gland,major,carcinoma,NS c.173C>T p.S58F 19:1632378-1632378 36
36 COSM6983856 SUZ12 salivary gland,major,carcinoma,NS c.766C>T p.R256C 17:31975656-31975656 36
37 COSM6951891 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 36
38 COSM6951889 STK40 salivary gland,major,carcinoma,NS c.97G>T p.G33* 1:36361236-36361236 36
39 COSM6939534 STAG2 salivary gland,major,carcinoma,NS c.2405T>G p.I802S 23:124071195-124071195 36
40 COSM6920823 STAG2 salivary gland,major,carcinoma,NS c.1808G>A p.G603E 23:124063192-124063192 36
41 COSM6924542 SPEN salivary gland,major,carcinoma,NS c.1648C>T p.R550C 1:15920882-15920882 36
42 COSM6939532 SOX9 salivary gland,major,carcinoma,NS c.1457T>A p.V486D 17:72124314-72124314 36
43 COSM6983831 SOX17 salivary gland,major,carcinoma,NS c.1181C>T p.A394V 8:54459931-54459931 36
44 COSM6939526 SMO salivary gland,major,carcinoma,NS c.385G>C p.V129L 7:129203437-129203437 36
45 COSM2769709 SMO salivary gland,major,carcinoma,NS c.1513C>T p.P505S 7:129210409-129210409 36
46 COSM4728291 SMARCA4 salivary gland,minor,carcinoma,NS c.2372C>T p.A791V 19:11013046-11013046 36
47 COSM1226761 SMARCA4 salivary gland,major,carcinoma,NS c.3967C>T p.R1323C 19:11034929-11034929 36
48 COSM6941870 SMARCA4 salivary gland,major,carcinoma,NS c.848C>G p.P283R 19:10986992-10986992 36
49 COSM1389051 SMAD4 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.993G>A p.M331I 18:51065460-51065460 36
50 COSM1658912 SLC26A2 salivary gland,mouth floor,carcinoma,NS c.1474C>T p.R492W 5:149981067-149981067 36

Expression for Salivary Gland Carcinoma

Search GEO for disease gene expression data for Salivary Gland Carcinoma.

Pathways for Salivary Gland Carcinoma

Pathways related to Salivary Gland Carcinoma according to KEGG:

37
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 12.6 NR4A1 MET KIT HGF EGFR
2
Show member pathways
12.59 MET KIT HGF EGFR CDKN2A
3
Show member pathways
12.54 MET MDM2 HGF EGFR CDKN2A
4 12.46 MET MDM2 KIT HGF EGFR CDKN2A
5
Show member pathways
12.43 MET MDM2 HGF EGFR
6 12.38 MET MDM2 EGFR CDKN2A
7 12.11 MET MDM2 HGF EGFR
8
Show member pathways
12.07 NR4A1 MET MDM2 KIT HGF EGFR
9
Show member pathways
12 NR4A1 MET MDM2 MAML2 KIT HGF
10 11.83 SOX2 MET ISL1 HGF
11 11.82 MDM2 EGFR CDKN2A
12 11.79 MET MDM2 HGF EGFR
13
Show member pathways
11.71 MET HGF EGFR
14 11.6 MDM2 EGFR CDKN2A
15 11.53 MET KIT EGFR
16 11.38 SOX2 KIT ISL1
17
Show member pathways
11.26 MET HGF EGFR
18 11.21 MET HGF EGFR
19 11.03 MET HGF EGFR
20 10.82 MET HGF
21 10.81 MET HGF EGFR

GO Terms for Salivary Gland Carcinoma

Biological processes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.73 MET KIT HGF EGFR
2 negative regulation of apoptotic process GO:0043066 9.71 MDM2 HGF EGFR
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.7 MET KIT EGFR
4 liver development GO:0001889 9.65 MET HGF EGFR
5 positive regulation of CREB transcription factor activity GO:0032793 9.56 CRTC3 CRTC1
6 positive regulation of protein kinase B signaling GO:0051897 9.56 MET KIT HGF EGFR
7 endocardial cushion morphogenesis GO:0003203 9.55 MDM2 ISL1
8 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.54 NR4A1 MDM2 HGF
9 tongue development GO:0043586 9.51 KIT EGFR
10 peptidyl-tyrosine phosphorylation GO:0018108 9.5 MET KIT EGFR
11 hepatocyte growth factor receptor signaling pathway GO:0048012 9.49 MET HGF
12 somatic stem cell division GO:0048103 9.46 KIT CDKN2A
13 amyloid fibril formation GO:1990000 9.4 MDM2 CDKN2A
14 positive regulation of transcription by RNA polymerase II GO:0045944 9.36 SOX2 NR4A1 NFIB MET MAML2 ISL1
15 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.16 MET HGF
16 positive regulation of MAPK cascade GO:0043410 8.96 SOX2 KIT

Molecular functions related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 5S rRNA binding GO:0008097 9.26 TST MDM2
2 cAMP response element binding protein binding GO:0008140 9.16 CRTC3 CRTC1
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 MET KIT EGFR
4 protein tyrosine kinase activity GO:0004713 8.8 MET KIT EGFR

Sources for Salivary Gland Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....